India has rightfully earned its reputation as the "Pharmacy of the World," manufacturing nearly one in every five generic medicines consumed globally and supplying vaccines to over 150 countries. However, a critical question remains largely unaddressed: how many truly indigenous pharmaceutical innovations has India produced since 2021? The answer is just eight.
Indigenous innovations come from a handful of firms
These eight innovations have emerged from only a few Indian companies, including Zydus Lifesciences, Wockhardt, Orchid Pharma, Biocon, ImmunoACT, and ENTOD Pharmaceuticals. They cover new chemical entities, biologics, immunotherapies, cell therapies, and novel drug formulations. According to the author, CEO of ENTOD Pharmaceuticals, these examples prove that Indian scientists and pharmaceutical companies possess the capability to innovate at the highest global standards.
Comparison with innovation economies is stark
Since 2021, the United States has produced nearly 500 meaningful pharmaceutical innovations, including around 160 new chemical entities (NCEs). China has delivered approximately 150 pharmaceutical innovations, including nearly 95 indigenous NCEs. India's tally, despite its scientific talent and manufacturing prowess, remains in single digits.
The challenge is no longer scientific capability but the ecosystem surrounding innovation. Developing a novel medicine demands years of research, clinical trials, regulatory scrutiny, and enormous financial investment with no guarantee of success.
Clinical data exclusivity is the missing piece
Every major pharmaceutical innovation ecosystem, including the United States, the European Union, and China, provides innovators with a period of regulatory data exclusivity. During this period, competitors cannot rely on the originator's clinical trial data to obtain marketing approval. This protection is distinct from patents and exists because innovators often spend 8-12 years generating the clinical evidence required for approval, by which time a significant portion of their patent life has already been exhausted.
India, however, provides no comparable framework for most indigenous pharmaceutical innovations. The author argues that a carefully designed clinical data exclusivity framework would have little impact on long-term affordability or patient access. Competition would still emerge after a defined period, just as it does in other major pharmaceutical markets. What it would do is encourage companies to invest in addressing unmet medical needs, fill important therapeutic gaps, accelerate indigenous drug discovery, improve health outcomes for the population, and create a stronger, higher-value pharmaceutical industry.
Investing in innovation is essential
It is no coincidence that the strongest voices advocating for such a framework are the Indian companies investing in indigenous pharmaceutical research. They understand that unless innovation is rewarded, innovation will remain the exception rather than the norm.
India has already mastered the art of reverse engineering, and that achievement transformed the nation into the Pharmacy of the World. The next chapter of India's pharmaceutical journey must be about forward engineering: discovering new molecules, developing breakthrough biologics and advanced therapies, and creating medicines that originate in Indian laboratories before reaching patients across the world.
India should not only be recognised as the nation that manufactures the world's medicines. It is time for India to become the nation that invents them.
